https://www.eurekalert.org/news-releases/1104745
metastatic her2+ breast cancer
Trastuzumab deruxtecan shows positive results in rare breast cancer with brain metastasis
?This solid evidence is seemingly leading into a new and groundbreaking BC treatment era.?
5-Nov-2025
Peer-Reviewed Publication
Impact Journals LLC
?This solid evidence is seemingly leading into a new and groundbreaking BC treatment era.?
BUFFALO, NY ? November 5, 2025 ? A new case report was published in Volume 12 of Oncoscience on October 9, 2025, titled "Metastatic breast cancer with leptomeningeal carcinomatosis treated with trastuzumab deruxtecan ? a case report."
In this report, Cristiana Honrado Martins, Jos? Miguel Rocha, Catarina Portela, Ricardo Fernandes, and Cl?udia Caeiro from Hospital de Braga, ULS de Braga, describe a rare case of advanced HER2-positive breast cancer (BC) that had spread to the membranes surrounding the brain and spinal cord?a condition known as leptomeningeal carcinomatosis.
The patient, a 37-year-old woman, initially responded to standard treatment but experienced a relapse two years later. At that point, her cancer had progressed to involve the central nervous system, severely affecting her neurological function. Given the complexity of her condition and limited standard options, the medical team initiated off-label treatment with trastuzumab deruxtecan.
Trastuzumab deruxtecan, a targeted antibody-drug conjugate, was selected based on data from recent clinical trials and multidisciplinary discussions. The patient began to improve after three treatment cycles. Imaging showed a reduction in the size and extent of the cancer, and her neurological symptoms gradually improved, allowing her to regain independence in daily activities. She continued on treatment for more than two years, during which the disease in her brain and spinal membranes remained stable.
This case illustrates the potential of antibody-drug conjugates like trastuzumab deruxtecan in treating breast cancers that reach the central nervous system. It also underscores the need for personalized and flexible treatment approaches in oncology, especially in cases of advanced or treatment-resistant breast cancer. Therapies like trastuzumab deruxtecan may become important tools for managing these types of tumors.
Continue reading:
https://doi.org/10.18632/oncoscience.631
Correspondence to: Cristiana Honrado Martins -
cristiana.honrado.martins@ulsb.min-saude.pt
Abstract video:
https://www.youtube.com/watch?v=7CplmXaDyvc
Keywords: cancer, breast cancer, leptomeningeal carcinomatosis, HER2 positive, antibody-drug conjugate, trastuzumab-deruxtecan
Click here to sign up for free Altmetric alerts about this article.
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication costs. It is free for the readers and the authors.
Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018?2022), and Dimensions (Digital Science).
Metastatic breast cancer with leptomeningeal carcinomatosis treated with trastuzumab deruxtecan ? a case report
Article Publication Date
9-Oct-2025
COI Statement
Authors have no conflicts of interest to declare.
Linear Mode
